Table 1.
Demographic and baseline characteristics across patients with Ph + CP CML.
| Characteristic | Line of treatment | Total (N = 156) | ||
|---|---|---|---|---|
| Second-line (n = 46) | Third-line (n = 61) | Fourth-line (n = 49) | ||
| Male, n (%) | 23 (50.0) | 37 (60.7) | 21 (42.9) | 81 (51.9) |
| Age, median (range), years | 54.0 (19.0–88.0) | 65.0 (27.0–85.0) | 61.0 (21.0–85.0) | 61.0 (19.0–88.0) |
| Age group, n (%) | ||||
| <65 years | 34 (73.9) | 30 (49.2) | 32 (65.3) | 96 (61.5) |
| ≥65 years | 12 (26.1) | 31 (50.8) | 17 (34.7) | 60 (38.5) |
| ECOG PS, n (%) | ||||
| 0 | 34 (73.9) | 40 (65.6) | 32 (65.3) | 106 (67.9) |
| 1 | 12 (26.1) | 20 (32.8) | 13 (26.5) | 45 (28.8) |
| 2 | 0 | 1 (1.6) | 4 (8.2) | 5 (3.2) |
| Median (range) duration since CML diagnosis, years | 2.2 (0.2–11.4) | 5.0 (0.3–18.6) | 7.3 (0.7–27.7) | 4.7 (0.2–27.7) |
| Prior TKI, n (%)a | ||||
| Imatinib | 35 (76.1) | 57 (93.4) | 49 (100) | 141 (90.4) |
| Dasatinib | 5 (10.9) | 41 (67.2) | 49 (100) | 95 (60.9) |
| Nilotinib | 6 (13.0) | 24 (39.3) | 49 (100) | 79 (50.6) |
| Prior interferon alpha, n (%) | 2 (4.3) | 3 (4.9) | 6 (12.2) | 11 (7.1) |
| Resistant to any prior TKI, n (%) | 17 (37.0) | 35 (57.4) | 31 (63.3) | 83 (53.2) |
| Intolerant to all prior TKIs, n (%) | 29 (63.0) | 26 (42.6) | 18 (36.7) | 73 (46.8) |
Full analysis set.
CML chronic myeloid leukemia, CP chronic phase, ECOG PS Eastern Cooperative Oncology Group performance status, Ph Philadelphia chromosome, TKI tyrosine kinase inhibitor.
aIn the third-line cohort, 37 (60.7%) of patients received prior imatinib and dasatinib, 20 (32.8%) of patients received prior imatinib and nilotinib and 4 (6.6%) of patients received prior dasatinib and nilotinib.